METHODS
The study was approved by the Human Research Ethics Committee of Sir Charles Gairdner Hospital. No additional blood sampling was necessary, so informed consent was not required. The study involved 40 elective cardiothoracic surgical patients who had received UH 5000 IU sc 12 hourly as routine DVT prophylaxis preoperatively. The prophylaxis had been commenced either the night before surgery or on the morning of surgery. In this way, all patients had received UH 5000 IU sc within six hours of surgery, but none had received more than two doses in the previous 24 hours. Patients were excluded if they had received any other heparin within the previous 72 hours, or warfarin or clopidogrel within the previous week, or if they had a known coagulopathy. Patients who had received aspirin or other non-steroidal medication were not excluded, because it is known that these drugs do not affect the TEG 12, 17 . Patients received their regular antihypertensive and anti-anginal medication, which varied among patients, but often included betaadrenergic blocking agents, oral nitrates, angiotensin converting enzyme inhibitors and calcium channel antagonists.
Blood samples were collected from an arterial cannula at the time of its insertion, prior to the induction of anaesthesia and without any heparincontaining solution priming the line. A two-syringe remove 5 ml deadspace blood (which was returned to the patient in a sterile manner intravenously), the second syringe to collect a 1 ml sample for TEG analysis. At the time of the study, TEG analysis was performed routinely on all elective cardiothoracic surgical patients in our institution.
The 1 ml of blood was added to a vial containing a kaolin activator (REF 6300, Haemoscope, Skokie, IL, U.S.A.) and mixed gently. Two separate samples of 0.36 ml each were then taken from the vial using a pipette. One sample was added to a standard TEG cup (REF 6211 Haemoscope, Skokie, IL, U.S.A.) (kaolin TEG). The other sample was added to another TEG cup containing 2 IU of lyophilised heparinase-I enzyme, (REF 6212 Haemoscope, Skokie, IL, channels were then run simultaneously (TEG 5000 ® , Haemoscope, Niles, IL, U.S.A.). The TEG channels were calibrated daily using an electronic maintenance test and were standardised weekly with biological controls. The channels chosen for the kaolin and In all cases the TEG runs were commenced within four minutes of blood collection.
The TEG R times (representing time to channels were recorded and the difference, if any, kaolin TEG R time >25% longer than the heparinasepatient weight, age, gender, preoperative creatinine concentration and time since last heparin dose.
Data analysis
The percentage of patients with a demonstrable heparin effect (kaolin TEG R time >25% longer was calculated. Similar calculations were made for the percentage of patients with a kaolin TEG R time >50% and >100% longer than their
The relationships between the percentage prolongation of TEG R times and patient weight, age, pre-operative creatinine concentration and time since last heparin were determined by calculating the
RESULTS
The mean age (±SD) of the patients was 63±9.9 years (range 42 to 79 years) and the mean weight was 80.8±17.1 kg (range 50 to 120 kg). There were 10 females. Individual details of each patient and their TEG R time data are presented in Table 1 .
Fourteen of the 40 patients (35%, 95% CI: 20 to 50%) had a heparin effect (TEG R time >25% (Table 1 ). In these patients, the mean (±SD) TEG R time for kaolin samples was 13.6±5.9 min (95% CI 10.5 to 16.7 min) (normal range 4 to 8 min) vs. 7.1±2.0 min (95% CI 5.9 to 8.1 min) for their remaining 26 patients had a mean TEG R time of 6.3±2.3 min, which was similar to their Of the fourteen patients with a heparin effect, 10 patients (25% of total, 95% CI 11.4 to 38.6%) had a TEG R time >50% longer than their these patients (10% of total, 95% CI 0.6 to 19.4%) had a TEG R time >100% longer than their Figure 3 . The relationship between patient weight and percentage prolongation of TEG R time is shown in Figure 4 .
DISCUSSION
The results indicate that about one third of cardiothoracic patients who have received low-dose UH within the previous six hours have a systemic heparin effect that can be demonstrated using TEG. This means that the possibility of some degree of systemic anticoagulation should be considered in patients who have recently received low-dose UH.
Although TEG is a non-standard laboratory coagulation test, there is now extensive experience with its use in the perioperative setting. Thrombelastography-based algorithms have led to improved coagulation management and reduced coagulation factor administration in several studies, indicating that the information it provides is clinically useful. The R time of the TEG is extremely sensitive to the presence of heparin. The R time represents the time to the commencement of levels of plasma clotting factors and circulating inhibitors [18] [19] [20] . Even very low concentrations of heparin (e.g. 0.28 IU/ml) may prolong the R time >60 minutes 12 was introduced to reverse the effects of heparin and allow other aspects of coagulation to be assessed in the presence of heparin (e.g. alpha angle ~ rate of clot formation; maximum amplitude ~ clot strength) 18 . Heparinase-I, which is isolated from Flavobacterium heparinum, an enzyme that degrades heparin into small inactive fragments without affecting other variables of coagulation [15] [16] . When simultaneous patient are compared, any difference must be due as a kaolin TEG R time >25% longer than the a heparin effect as any value outside the normal range corrected by heparinase 13, 21 . However, we chose as to be considered potentially clinically relevant. Nevertheless, the choice of 25% may be considered relatively arbitrary. Therefore we included results for >50% and >100% prolongation. TEG values within these ranges in cardiothoracic surgical patients post cardiopulmonary bypass would prompt immediate treatment with further protamine or even fresh frozen plasma 21, 22 .
technique is that each patient acts as their own control, robust than a comparison of two different patient groups or comparison of an individual result with a population mean or normal range. of patients receiving low-dose UH is not new. Previous studies suggest that the activated partial thromboplastin time (APTT) may be elevated in up to 15% of patients and therapeutic anticoagulation may be observed in 2 to 4% 3 . However, the APTT effect related to low-dose UH using a highly sensitive TEG.
This study was not designed to identify factors that may contribute to the development of a systemic heparin effect in patients receiving low-dose UH. However, post hoc analysis suggests that there was little relationship between the percentage prolongation in TEG R times and patient age (r=0.02) or preoperative creatinine concentration (r=-0.17). Similarly, there was little relationship to time since last heparin dose (r=0.14), although all but two abnormal values were in patients who had received UH within four hours (Figure 3 ). There was a slightly greater relationship between percentage prolongation in TEG R time and patient weight (r=-0.31), with the majority of abnormal values occurring in patients of lower weight (Figure 4 ). Nevertheless, due to the small number of patients, are required to identify factors contributing to the presence of a heparin effect, and the extent of the heparin effect, in patients receiving low-dose UH.
A major concern with abnormal coagulation in surgical patients is the risk of epidural haematoma if CNB is used. Fortunately, epidural haematoma with CNB is rare, even in patients with impaired coagulation. Nevertheless, due to the potentially devastating consequences, even an extremely low risk may be considered unacceptable. The baseline risk in patients with normal coagulation is probably <1:150,000 3 . However, the risk increases 10 to 100 fold in anticoagulated patients 3 . For this reason, there have been extensive recommendations for the safe use of CNB in patients with potentially impaired coagulation, including patients receiving low-dose UH 3,5-8 .
The most recent American Society of Regional Anesthesia (ASRA) guidelines state that "there is no contraindication to the use of CNB" in the presence of low-dose UH and do not recommend observing a safe interval between heparin administration and CNB 3 . Nevertheless, as recently as 2002, Warkentin and Crowther recommended a delay of "at least 8 to 12 hours" between administration of low-dose sc UH and CNB 5 . More recently, the German Society of Anaesthesiology and Intensive Care Medicine recommended a fourhour delay between low-dose UH administration and CNB 6 . In 2006, Mulroy advised avoiding CNB during the peak levels of heparin (e.g. two hours post-injection) 7 . Brown, in the most recent edition of Miller's Anesthesia, states that the "use of epidural techniques in patients receiving sc UH is probably acceptable if the block can be performed atraumatically" 8 . Given that there is never a 100% guarantee that a block will be atraumatic, many anaesthetists would consider this a recommendation to avoid CNB in patients receiving low-dose UH. All but one of these guidelines indicate that concern about the safety of CNB in the presence of low dose UH still exists, although the risk may be considered extremely low. Even the most recent ASRA guidelines introduce some concern by stating that "the risk of neuraxial bleeding may be reduced by delay of the heparin injection until after the block" 3 .
information about the risks of CNB in patients receiving low-dose UH. Such a study would require the randomisation of thousands, if not tens of thousands, of patients 17 
